BTN3A1 and esophageal squamous cell carcinoma: Based on the above results, we suggest that BTN3A1 knockdown sensitizes ESCC cells to IR and that BTN3A1 inhibitor could be developed as drugs to improve radiotherapy efficacy in ESCC patients.